Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

258 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Body composition as a determinant of the therapeutic index with androgen signaling inhibition.
Hahn AW, Tidwell RS, Pilie PG, Yu Y, Liu J, Surasi DS, Titus M, Zhang J, Venkatesh N, Panaretakis T, Gregg JR, Zurita AJ, Siddiqui BA, Corn PG, Subudhi SK, Msaouel P, Koutroumpakis E, Huff CD, Aparicio A, McQuade JL, Frigo DE, Logothetis CJ. Hahn AW, et al. Among authors: titus m. Prostate Cancer Prostatic Dis. 2024 Jul 17. doi: 10.1038/s41391-024-00870-8. Online ahead of print. Prostate Cancer Prostatic Dis. 2024. PMID: 39019979
Characterization of prostate cancer adrenal metastases: dependence upon androgen receptor signaling and steroid hormones.
Sakellakis MJ, Hahn AW, Ramachandran S, Zhang M, Hoang A, Song JH, Liu J, Wang F, Basu HS, Sheperd P, Wang X, Frigo DE, Lin SH, Panaretakis T, Zhang J, Navone N, Troncoso P, Logothetis CJ, Titus MA. Sakellakis MJ, et al. Among authors: titus ma. Prostate Cancer Prostatic Dis. 2023 Dec;26(4):751-758. doi: 10.1038/s41391-022-00590-x. Epub 2022 Sep 13. Prostate Cancer Prostatic Dis. 2023. PMID: 36100698
A Phase II Study of Cabozantinib and Androgen Ablation in Patients with Hormone-Naïve Metastatic Prostate Cancer.
Corn PG, Zhang M, Nogueras-Gonzalez GM, Xiao L, Zurita AJ, Subudhi SK, Tu SM, Aparicio AM, Coarfa C, Rajapakshe K, Huang S, Navone NM, Lin SH, Wang G, Ramachandran S, Titus MA, Panaretakis T, Gallick GE, Efstathiou E, Troncoso P, Logothetis C. Corn PG, et al. Among authors: titus ma. Clin Cancer Res. 2020 Mar 1;26(5):990-999. doi: 10.1158/1078-0432.CCR-19-2389. Epub 2020 Jan 15. Clin Cancer Res. 2020. PMID: 31941830 Clinical Trial.
Monitoring Glucocorticoid Receptor in Plasma-derived Extracellular Vesicles as a Marker of Resistance to Androgen Receptor Signaling Inhibition in Prostate Cancer.
Gentile E, Hahn AW, Song JH, Hoang A, Shepherd PDA, Ramachandran S, Navone NM, Efstathiou E, Titus M, Corn PG, Lin SH, Logothetis CJ, Panaretakis T. Gentile E, et al. Among authors: titus m. Cancer Res Commun. 2023 Dec 13;3(12):2531-2543. doi: 10.1158/2767-9764.CRC-23-0362. Cancer Res Commun. 2023. PMID: 37930121 Free PMC article.
Androgen Receptor Signaling in Castration-Resistant Prostate Cancer Alters Hyperpolarized Pyruvate to Lactate Conversion and Lactate Levels In Vivo.
Zacharias N, Lee J, Ramachandran S, Shanmugavelandy S, McHenry J, Dutta P, Millward S, Gammon S, Efstathiou E, Troncoso P, Frigo DE, Piwnica-Worms D, Logothetis CJ, Maity SN, Titus MA, Bhattacharya P. Zacharias N, et al. Mol Imaging Biol. 2019 Feb;21(1):86-94. doi: 10.1007/s11307-018-1199-6. Mol Imaging Biol. 2019. PMID: 29748904 Free PMC article.
Subtype and Site Specific-Induced Metabolic Vulnerabilities in Prostate Cancer.
Mossa F, Robesti D, Sumankalai R, Corey E, Titus M, Kang Y, Zhang J, Briganti A, Montorsi F, Vellano CP, Marszalek JR, Frigo DE, Logothetis CJ, Gujral TS, Dondossola E. Mossa F, et al. Among authors: titus m. Mol Cancer Res. 2023 Jan 3;21(1):51-61. doi: 10.1158/1541-7786.MCR-22-0250. Mol Cancer Res. 2023. PMID: 36112348 Free PMC article.
258 results